A citation-based method for searching scientific literature

Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
Times Cited: 72



Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
Times Cited: 196




List of shared articles



Times cited


An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
50


Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Nicola Fleming, Peter Shane Hamblin, David Story, Elif I Ekinci. J Clin Endocrinol Metab 2020
8

Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
Rachel J Perry, Aviva Rabin-Court, Joongyu D Song, Rebecca L Cardone, Yongliang Wang, Richard G Kibbey, Gerald I Shulman. Nat Commun 2019
36

Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Young-Gun Kim, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Kwan-Woo Lee, Hae Jin Kim. Diabetes Obes Metab 2018
24

Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
1

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Emily Brown, John Ph Wilding, Uazman Alam, Thomas M Barber, Janaka Karalliedde, Daniel J Cuthbertson. Ann Med 2020
2

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
35